Sermorelin and CJC-1295 are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Same signal, two timescales
Sermorelin and CJC-1295 belong to the same pharmacological family: both are synthetic analogues of growth hormone-releasing hormone (GHRH), and both act on the GHRH receptor on somatotroph cells in the anterior pituitary to drive endogenous growth hormone (GH) release. Where they diverge is not what they do but how long they do it for. Sermorelin reproduces the native GHRH signal almost exactly — and, like the native hormone, it clears in minutes. CJC-1295 takes the same 29-residue backbone and re-engineers it to resist degradation and, in its Drug Affinity Complex (DAC) form, to loiter in circulation for the best part of a week. The comparison below is really a study in duration of action: a short, physiological pulse against a long, sustained stimulus.
| Sermorelin | CJC-1295 | |
|---|---|---|
| Class / peptide type | GHRH analogue — GRF (1-29), native fragment | GHRH analogue — Mod GRF (1-29), tetrasubstituted |
| Primary target | GHRH-R (pituitary) → cAMP → GH secretion | GHRH-R (anterior pituitary) → cAMP/PKA → GH secretion |
| Structure / MW note | Shortest fully active GHRH fragment; 29 amino acids | 29 aa, substituted at positions 2, 8, 15, 27; ~3647 g/mol (no DAC) |
| Half-life / duration | ~11 minutes | ~30 min (no DAC); 5.8–8.1 days (with DAC) |
| Main research focus | Pulsatile GH release, preserved feedback, ageing GH axis | Sustained GH/IGF-1 elevation, body composition, PK/PD |
| Typical pairing | GHS such as ipamorelin | GHS such as ipamorelin (dual-pathway protocols) |
| Regulatory status | Formerly FDA-approved, now withdrawn | Never FDA-approved; investigational |
Sermorelin: the native, short-acting fragment
Sermorelin — GRF (1-29) NH₂ — is a 29-amino acid synthetic analogue of the first 29 residues of endogenous GHRH, and represents the shortest fully active GHRH fragment. In practice that means it behaves almost identically to the body's own releasing hormone. It binds the GHRH receptor on pituitary somatotrophs, activates the cAMP/PKA cascade and stimulates endogenous GH gene transcription, but because its half-life is only around 11 minutes the resulting GH release is brief and episodic rather than continuous.
That short duration is the point, not a limitation. Sermorelin's most distinctive property is that it preserves the hypothalamic-pituitary negative feedback loop: because it prompts the pituitary to make its own GH rather than introducing GH directly, somatostatin can still regulate the system and the pulsatile release pattern is retained — more closely mimicking normal physiology than a constant-infusion approach. A 2009 review in Clinical Interventions in Aging (PMC2699646) also documented that sermorelin stimulates pituitary GH mRNA transcription, increasing pituitary reserve. Its well-characterised pharmacology and historical approval status make it a natural reference compound in GH-axis research, and its brevity is exactly what has driven interest in longer-acting analogues. Researchers sourcing material can buy Sermorelin UK in research-grade form with a COA.
CJC-1295: the engineered, long-acting analogue
CJC-1295 starts from the same GRF (1-29) template but modifies it at four amino acid positions (2, 8, 15, 27) to resist enzymatic degradation — the tetrasubstituted form often called Mod GRF 1-29, with a molecular weight of roughly 3647 g/mol and a half-life of about 30 minutes on its own. The step change comes with the DAC (Drug Affinity Complex) modification: a maleimidyl linker binds covalently to cysteine-34 on circulating albumin, exploiting albumin's long half-life to create a sustained-release depot. That extends the circulating half-life to 5.8–8.1 days, making it the longest-acting GHRH analogue with published human pharmacokinetic data.
The downstream mechanism mirrors sermorelin — GHRHR binding, cAMP/PKA activation, enhanced GH gene transcription and vesicle exocytosis — but the kinetics are transformed. In the principal human PK/PD trial (JCEM, 2006, PMID 16352683), single subcutaneous injections of CJC-1295 with DAC elevated mean GH concentrations for six or more days and IGF-1 for 9–11 days; after repeated dosing, IGF-1 remained above baseline for up to 28 days. Rather than a pulse that fades, the DAC form holds the GHRH receptor under prolonged, sustained stimulation. You can review the full pharmacology on the CJC-1295 knowledgebase page, or buy CJC-1295 UK across multiple strengths.
What the differences mean in a research context
Because both compounds hit the same receptor through the same cascade, they are best understood as a controlled contrast in duration of action. Hold the target constant and vary only how long the signal persists, and you can probe two quite different questions. Sermorelin models the physiological case: brief, pulsatile GH release under intact somatostatin feedback, where the system self-limits and the natural rhythm of secretion is preserved. It is the tool of choice when the research interest is the integrity of the GH neuroendocrine axis itself — pituitary reserve, feedback, and the age-related decline of that axis.
CJC-1295, especially with DAC, models the opposite: sustained, non-pulsatile GHRH tone and the maintained IGF-1 elevation that follows. That makes it the more practical probe for downstream, longer-horizon endpoints such as body composition, where a signal measured in minutes is simply too transient to study. The trade-off is that continuous stimulation departs from native physiology, and the regulatory picture differs too. Sermorelin was previously FDA-approved (for paediatric growth disorders) before commercial withdrawal, whereas CJC-1295 has never been approved; the FDA has flagged immunogenicity and cardiovascular concerns (flushing, transient hypotension) for GHRH analogues in compounding. Both remain research reagents here, supplied for in vitro use only.
It is worth noting that the two are not mutually exclusive as research tools. Both are commonly studied alongside a growth-hormone secretagogue such as ipamorelin, which acts on a separate receptor population, in dual-pathway GH-axis protocols.
The bottom line
Sermorelin and CJC-1295 are the same GHRH signal delivered on different clocks. Sermorelin is the short, native fragment — minutes-long, pulsatile, feedback-preserving — best suited to studying the physiology of the GH axis. CJC-1295 is the engineered long-acting analogue — days-long with DAC, sustained, IGF-1-driving — best suited to downstream metabolic endpoints. Neither is "better"; they answer different questions. For research-grade material with ≥99% purity and a COA, see our pages to buy Sermorelin UK and buy CJC-1295 UK.